Table 3 Multivariate analyses of recurrence-free survival and distant recurrence-free survival in this cohort.

From: Clinical relevance of pathogenic germline variants in mismatch repair genes in Chinese breast cancer patients

Variable

RFS

 

DRFS

HR (95% CI)

P

 

HR (95% CI)

P

Age

     

 ≤40 yr

1.00

–

 

1.00

–

 >40 yr

0.78 (0.66–0.94)

0.007

 

0.90 (0.73–1.10)

0.28

Tumor size

     

 ≤2 cm

1.00

–

 

1.00

–

 >2 cm

1.57 (1.32–1.86)

<0.001

 

1.73 (1.43–2.09)

<0.001

Lymph node

     

 Negative

1.00

–

 

1.00

–

 Positive

3.41 (2.92–3.98)

<0.001

 

3.59 (3.03–4.25)

<0.001

Grade

     

 I

1.00

–

 

1.00

–

 II

1.34 (0.99–1.82)

0.06

 

1.45 (1.03–2.04)

0.03

 III

1.38 (0.97–1.98)

0.07

 

1.49 (1.00–2.21)

0.05

ER status

     

 Negative

1.00

–

 

1.00

–

 Positive

0.73 (0.56–0.94)

0.01

 

0.77 (0.58–1.01)

0.06

PR status

     

 Negative

1.00

–

 

1.00

–

 Positive

0.75 (0.60–0.94)

0.01

 

0.73 (0.57–0.92)

0.009

HER2 status

     

 Negative

1.00

–

 

1.00

–

 Positive

1.13 (0.96–1.34)

0.15

 

1.18 (0.98–1.41)

0.08

Treatment

     

 No treatment

1.00

–

 

1.00

–

 C vs. no treatment

1.09 (0.77–1.55)

0.63

 

0.94 (0.65–1.36)

0.74

 E vs. no treatment

1.22 (0.86–1.73)

0.28

 

1.06 (0.73–1.53)

0.78

 C + E vs. no treatment

1.03 (0.69–1.56)

0.87

 

0.88 (0.57–1.36)

0.56

Pathogenic variants

     

 Non-carriers

1.00

–

 

1.00

–

 MMR carriers

2.34 (0.97–5.66)

0.06

 

2.76 (1.14–6.69)

0.03

  1. RFS recurrence-free survival, DRFS distant recurrence-free survival, CI confidence interval, C chemotherapy, E endocrine therapy, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, HR hazard ratio, MMR mismatch repair.
Back to article page